Novel Dosage Forms and Regimens for Sevelamer-Based Phosphate Binders

Journal of Renal Nutrition

Volumn 16, Issue 3, 2006, Pages 248-252

  Duggal, Ajay ^a   Hanus, Martin ^b   Zhorov, Eugene ^b   Dagher, Rafif ^b   Plone, Melissa A ^b   Goldberg, Jeffrey ^b   Burke, Steven K ^b  

^a Genzyme Europe Research   (United Kingdom)

^b Genzyme Drug Discovery and Development   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BICARBONATE; CHLORIDE; PHOSPHATE; PHOSPHORUS; POLYAMINE; SEVELAMER;

ANIMAL; ARTICLE; BLOOD; CHEMISTRY; CHRONIC KIDNEY FAILURE; DOG; HUMAN; KINETICS; PATIENT COMPLIANCE; RENAL REPLACEMENT THERAPY;

ANIMALS; BICARBONATES; CHLORIDES; DOGS; HUMANS; KIDNEY FAILURE, CHRONIC; KINETICS; PATIENT COMPLIANCE; PHOSPHATES; PHOSPHORUS; POLYAMINES; RENAL DIALYSIS;

EID: 33745667513     PISSN: 10512276     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.jrn.2006.04.006     Document Type: Article

References (19)

1. Chertow G.M., Burke S.K., Lazarus J.M., et al. Poly[allylamine hydrochloride] (RenaGel). a noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure. Am J Kidney Dis 29 (1997) 66-71
2. Goldberg D.I., Dillon M.A., Slatopolsky E.A., et al. Effect of RenaGel, a non-absorbed, calcium- and aluminium-free phosphate binder, on serum phosphorus, calcium, and intact parathyroid hormone in end-stage renal disease patients. Nephrol Dial Transplant 13 (1998) 2303-2310
3. Chertow G.M., Dillon M., Burke S.K., et al. A randomized trial of sevelamer hydrochloride (RenaGel) with and without supplemental calcium. Strategies for the control of hyperphosphatemia and hyperparathyroidism in hemodialysis patients. Clin Nephrol 51 (1999) 18-26
4. Bleyer A.J., Burke S.K., Dillon M., et al. A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients. Am J Kidney Dis 33 (1999) 694-701
5. Slatopolsky E.A., Burke S.K., Dillon M.A., and The RenaGel Study Group. RenaGel, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone. Kidney Int 55 (1999) 299-307
6. Chertow G.M., Burke S.K., Dillon M.A., et al. Long-term effects of sevelamer hydrochloride on the calcium × phosphate product and lipid profile of haemodialysis patients. Nephrol Dial Transplant 14 (1999) 2907-2914
7. Raggi P., Boulay A., Chasan-Taber S., et al. Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease?. J Am Coll Cardiol 39 (2002) 695-701
8. Chertow G.M., Burke S.K., and Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 62 (2002) 245-252
9. Chertow G.M., Raggi P., Chasan-Taber S., et al. Determinants of progressive vascular calcification in haemodialysis patients. Nephrol Dial Transplant 19 (2004) 1489-1496
10. Chertow G.M., Raggi P., McCarthy J.T., et al. The effects of sevelamer and calcium acetate on proxies of atherosclerotic and arteriosclerotic vascular disease in hemodialysis patients. Am J Nephrol 23 (2003) 307-314
11. Asmus H.G., Braun J., Krause R., et al. Two year comparison of sevelamer and calcium carbonate effects on cardiovascular calcification and bone density. Nephrol Dial Transplant 20 (2005) 1653-1661
12. Block G.A., Spiegel D.M., Ehrlich J., et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 68 (2005) 1815-1824
13. Block G.A., Hulbert-Shearon T., Levin N., et al. Association of serum phosphorus and calcium × phosphate product with mortality risk in chronic hemodialysis patients. a national study. Am J Kidney Dis 31 (1998) 607-617
14. Young E.W., Albert J.M., Satayathum S., et al. Predictors and consequences of altered mineral metabolism. the Dialysis Outcomes and Practice Patterns Study. Kidney Int 67 (2005) 1179-1187
15. Tomasello S., Dhupar S., and Sherman R.A. Phosphate binders, K/DOQI Guidelines, and compliance. the unfortunate reality. Dial Transplant 33 (2004) 238-241 291
16. Cleary D.J., Matzke G.R., Alexander A.C., et al. Medication knowledge and compliance among patients receiving long-term dialysis. Am J Health Syst Pharm 52 (1995) 1895-1900
17. Claxton A.J., Cramer J., and Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 23 (2001) 1296-1310
18. Plone M.A., Petersen J.S., Rosenbaum D.P., et al. Sevelamer, a phosphate-binding polymer, is a non-absorbed compound. Clin Pharmacokinet 41 (2002) 517-523
19. Fischer D., Cline K., Plone M., et al. A randomized, cross-over study to compare once a day with three times per day sevelamer dosing. Nephrol Dial Transplant 20 suppl 5 (2005) v93